|
Mordyk A.V., Viktorova I.A., Antipova E.P., Streltsova V.V., Bagisheva N.V., Moiseeva M.V.
Clinical features of arterial hypertension against the background of acute respiratory viral infection of various etiologies
|
№4 / 2025
|
|
L.Yu. Khamnueva, L.S. Andreeva, M.A. Gryaznova, E.A. Danilova, A.G. Basayeva
Pheochromocytoma in an elderly patient (case report)
|
№2 / 2025
|
|
S.A. Babanov, L.A. Strizhakov, N.E. Lavrentyeva, V.S. Lotkov, M.Yu. Vostroknutova, I.N. Vasina, A.S. Babanov, M.S. Artemyeva
Immunopathogenetic features, diagnostics and prognosis in occupational chronic obstructive pulmonary disease and its comorbid forms
|
№1 / 2025
|
|
E.V. Rebrova, E.V. Shikh
Assessment of the effect of minimum steady-state concentrations of angiotensin II receptor blockers on the dynamics of office blood pressure values in patients with newly diagnosed stage 1–2 arterial hypertension
|
№1 / 2025
|
|
Sychev I.V., Denisenko N.P., Lapshtaeva A.V., Kachanova A.A., Abdullaev Sh.P., Kupriyanov Yu.Yu., Goncharova L.N., Mirzaev K.B., Sychev D.A.
Development of an algorithm for predicting the risk of cough development during enalapril therapy in patients with arterial hypertension
|
№9 / 2024
|
|
E.V. Rebrova, E.V. Shikh, S.A. Solovieva, G.G. Melkonyan, N.P. Kulagina
Analysis of associations of polymorphic markers of the CYP2C9, AGTR1, AGT, ACE, CYP11B2 genes with the achievement of target blood pressure values in patients with newly diagnosed arterial hypertension 1-2 degree after 3 weeks of pharmacotherapy with angiotensin II receptor blockers
|
№9 / 2024
|
|
Ignatenko G.A., Bagriy A.E., Mikhailichenko E.S., Prikolota A.V., Mogilevskaya K.E., Sabelnikova Ya.S., Belikov V.A.
Potentials for the use of azilsartan and spironolactone in patients with arterial hypertension and diabetes mellitus
|
№8 / 2024
|
|
Gorban V.V., Gerasimenko I.A., Kovrigina I.V., Kameneva E.S., Gorban E.V.
Realities of complex therapy of lipitension in comorbid patients at the outpatient stage
|
№6 / 2024
|
|
Minushkina L.O.
Treatment of arterial hypertension in the elderly: therapeutic strategy and features of drug therapy
|
№6 / 2024
|
|
Mubarakshina O.A., Somova M.N., Batishcheva G.A., Zhdanova O.A., Kurbatova E.I.
Clinical and pharmacological assessment of the combination of valsartan and amlodipine for the treatment of arterial hypertension against the background of comorbidity
|
№4 / 2024
|
|
Shuvalova A.S., Prokofieva T.V., Polunina O.S., Polunina E.A.
Association of N-terminal pro C-type natriuretic peptide and endothelin-1 levels with the risk of cardiovascular complications in arterial hypertension six months after COVID-19
|
№1 / 2024
|
|
E.V. Rebrova, E.V. Shikh, R.E. Kazakov, G.G. Melkonyan, N.P. Kulagina
Analysis of the frequency of CYP2C9, AGTR1, AGT, ACE, CYP11B2 gene Polymorphisms occurrence in patients with newly diagnosed 1–2 degree arterial hypertension
|
№14 / 2023
|
Русский
